MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin diseases, today announced the hiring of Joyce Rico, MD, MBA, FAAD, as Chief Medical Officer. Dr. Rico has over 20 years of experience in early and late-stage dermatology
drug development, product launch, and drug safety.
Interim results of a Phase 1b trial of cirmtuz umab and paclitaxel in locally advanced/unresectable or metastatic HER2-negative breast cancer compare favorably to historical single-agent paclitaxel da
- First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA® (lefamulin) and SIVEXTRO® (tedizolid phosphate) in the community- - Commenced exclusive distribut
Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients https://
